Literature DB >> 29557411

The Variant rs145204276 of GAS5 is Associated with the Development and Prognosis of Gastric Cancer.

Qian Jun Li1, Gang Ma1, Hui Min Guo2, Su Hua Sun1, Ying Xu1, Bing Jian Wang3.   

Abstract

BACKGROUND AND AIMS: Down-regulation of the growth arrest specific transcript 5 (GAS5) (long non-coding RNA) is associated with cell proliferation of gastric cancer (GC) and a poor prognosis. We aimed to investigate whether the variant rs145204276 of GAS5 is associated with the prognosis of GC in the Chinese population, and to unveil the regulatory mechanism underlying the GAS5 expression in GC tissues.
METHOD: 1,253 GC patients and 1,354 healthy controls were included. The frequency of the genotype del/del and the allele del of rs145204276 were compared between the patients and the controls and between different subgroups of patients classified by clinicopathological variables. The overall survival rate was analyzed according to the Kaplan-Meier method using the log-rank test.
RESULTS: The frequency of genotype del/del was significantly lower in patients than in the controls (7.0% vs. 9.1%, p = 0.001). Kaplan-Meier analysis showed that genotype del/del was significantly associated with a higher survival rate (p = 0.01). Patients with late tumor stage were found to have a significantly lower rate of genotype del/del than those with an early tumor stage (4.9% vs. 8.8%, p = 0.01). Patients with UICC III and IV were found to have a significantly lower rate of genotype del/del than those with UICC I and II (5.3% vs. 8.1%, p = 0.02).
CONCLUSION: The variant rs145204276 of GAS5 is associated with the development and prognosis of GC. The allele del of rs145204276 is associated with a remarkably lower incidence of cancer progression and metastasis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29557411     DOI: 10.15403/jgld.2014.1121.271.qjl

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  5 in total

1.  Novel Tumor Suppressor lncRNA Growth Arrest-Specific 5 (GAS5) In Human Cancer.

Authors:  Yaya Yu; Swei Sunny Hann
Journal:  Onco Targets Ther       Date:  2019-10-11       Impact factor: 4.147

2.  Impact of LncRNA GAS5 Genetic Variants and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma Patients.

Authors:  Ming-Hong Hsieh; Yi-Liang Wu; Thomas Chang-Yao Tsao; Yi-Wen Huang; Jian-Cheng Lin; Chia-Yi Lee; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2022-08-12       Impact factor: 4.614

3.  Association between lncRNA GAS5, MEG3, and PCAT-1 Polymorphisms and Cancer Risk: A Meta-Analysis.

Authors:  Xiaoyan Dong; Wenyan Gao; Xiaoling Lv; Yazhen Wang; Qing Wu; Zhouxin Yang; Genxiang Mao; Wenmin Xing
Journal:  Dis Markers       Date:  2020-03-28       Impact factor: 3.434

4.  Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics.

Authors:  Chia-Yen Lin; Shian-Shiang Wang; Cheng-Kuang Yang; Jian-Ri Li; Chuan-Shu Chen; Sheng-Chun Hung; Kun-Yuan Chiu; Chen-Li Cheng; Yen-Chuan Ou; Shun-Fa Yang
Journal:  Int J Med Sci       Date:  2019-09-20       Impact factor: 3.738

5.  The relationships of genetic polymorphisms of the long noncoding RNA growth arrest-specific transcript 5 with uterine cervical cancer.

Authors:  Shun-Long Weng; Soo-Cheen Ng; Yueh-Chun Lee; Yi-Hsuan Hsiao; Chun-Fang Hsu; Shun-Fa Yang; Po-Hui Wang
Journal:  Int J Med Sci       Date:  2020-05-18       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.